Havemeyer Place LP Makes New Investment in United Therapeutics Corporation $UTHR

Havemeyer Place LP purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,493 shares of the biotechnology company’s stock, valued at approximately $2,189,000.

Several other institutional investors have also added to or reduced their stakes in the business. Clearstead Advisors LLC boosted its holdings in United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 23 shares in the last quarter. Independent Advisor Alliance boosted its holdings in United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 27 shares in the last quarter. Bessemer Group Inc. boosted its holdings in United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after acquiring an additional 28 shares in the last quarter. Florida Financial Advisors LLC boosted its holdings in United Therapeutics by 5.4% in the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after acquiring an additional 28 shares in the last quarter. Finally, Signaturefd LLC boosted its holdings in United Therapeutics by 4.1% in the fourth quarter. Signaturefd LLC now owns 896 shares of the biotechnology company’s stock worth $437,000 after acquiring an additional 35 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.4%

Shares of NASDAQ:UTHR opened at $549.87 on Friday. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The stock has a market cap of $23.34 billion, a price-to-earnings ratio of 20.30, a PEG ratio of 1.79 and a beta of 0.57. The business has a 50-day moving average price of $568.23 and a 200-day moving average price of $518.83.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.63 earnings per share. As a group, equities analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. HC Wainwright raised their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Raymond James Financial began coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 624,043 shares of company stock worth $351,649,680 in the last three months. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.